{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:14:20Z","timestamp":1784945660998,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.diabet.2020.08.005","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T12:04:52Z","timestamp":1599653092000},"page":"101190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial"],"prefix":"10.1016","volume":"47","author":[{"given":"Niels H.","family":"Brandt-Jacobsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Louise","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2898-1771","authenticated-orcid":false,"given":"Jon","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-0869","authenticated-orcid":false,"given":"Julie L.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Refsgaard","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kistorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2020.08.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072860","article-title":"The Gap between Estimated Incidence of End-Stage Renal Disease and Use of Therapy","volume":"8","author":"Anand","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2020.08.005_bib0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2020.08.005_bib0015","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jchf.2018.01.009","article-title":"Obesity-Related Heart Failure With a Preserved Ejection Fraction","volume":"6","author":"Packer","year":"2018","journal-title":"JACC Hear Fail"},{"key":"10.1016\/j.diabet.2020.08.005_bib0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabet.2020.08.005_bib0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.diabet.2020.08.005_bib0030","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2020.08.005_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin\u2013angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses","volume":"13","author":"Catal\u00e1-L\u00f3pez","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.diabet.2020.08.005_bib0040","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes - 2019","volume":"42","author":"Care","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2020.08.005_bib0045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12933-019-0837-x","article-title":"Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases","volume":"18","author":"Bramlage","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2020.08.005_bib0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/XCE.0000000000000135","article-title":"Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care","volume":"6","author":"Rungby","year":"2017","journal-title":"Cardiovasc Endocrinol"},{"key":"10.1016\/j.diabet.2020.08.005_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.diabet.2020.08.005_bib0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2020.08.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13809","article-title":"Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double\u2010blind, placebo\u2010controlled trial (MIRAD trial)","author":"Johansen","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2020.08.005_bib0070","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2020.08.005_bib0075","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1007\/s00125-006-0359-4","article-title":"Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes","volume":"49","author":"Tarnow","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2020.08.005_bib0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MBP.0b013e328338892f","article-title":"Validation of the mobil-O-Graph: 24h-blood pressure measurement device","volume":"15","author":"Wei","year":"2010","journal-title":"Blood Press Monit"},{"key":"10.1016\/j.diabet.2020.08.005_bib0085","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/HJH.0b013e328363e964","article-title":"European society of hypertension position paper on ambulatory blood pressure monitoring","volume":"31","author":"O\u2019Brien","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.diabet.2020.08.005_bib0090","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/ndt\/gft003","article-title":"Estimating GFR using the chronic kidney disease epidemiology collaboration (CKD-EPI) 2009 creatinine equation: the time for change is now","volume":"28","author":"Inker","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.diabet.2020.08.005_bib0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.diabet.2020.08.005_bib0100","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1002\/sim.3639","article-title":"Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?","volume":"28","author":"Liu","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.diabet.2020.08.005_bib0105","first-page":"1","article-title":"Guideline on missing data in confirmatory clinical trials","volume":"44","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2010","journal-title":"London Eur Med Agency"},{"key":"10.1016\/j.diabet.2020.08.005_bib0110","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1172\/JCI102501","article-title":"Water diuresis produced during recumbency by the intravenous infusion","volume":"30","author":"Strauss","year":"1951","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2020.08.005_bib0115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B"},{"key":"10.1016\/j.diabet.2020.08.005_bib0120","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2020.08.005_bib0125","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"2014","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.diabet.2020.08.005_bib0130","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2020.08.005_bib0135","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of Eplerenone, Enalapril, and Eplerenone\/Enalapril in Patients With Essential Hypertension and Left Ventricular Hypertrophy","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2020.08.005_bib0140","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.2337\/dc19-0349","article-title":"Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function\u2014even without albuminuria","volume":"42","author":"Vistisen","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2020.08.005_bib0145","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/01.HYP.0000025904.23047.27","article-title":"Mineralocorticoid and Angiotensin Receptor Antagonism During Hyperaldosteronemia","volume":"40","author":"Mihailidou","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2020.08.005_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jphs.10R07CR","article-title":"Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney","volume":"115","author":"Rafiq","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.diabet.2020.08.005_bib0155","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1681\/ASN.2006080944","article-title":"Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors","volume":"17","author":"Nagase","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.diabet.2020.08.005_bib0160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.111.173195","article-title":"Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors","volume":"59","author":"Fu","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2020.08.005_bib0165","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/nm.1879","article-title":"Modification of mineralocorticoid receptor function by Rac1 GTPase: Implication in proteinuric kidney disease","volume":"14","author":"Shibata","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2020.08.005_bib0170","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2020.08.005_bib0175","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ejhf.792","article-title":"Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial","volume":"19","author":"Olivier","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2020.08.005_bib0180","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and\/or Chronic Kidney Disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.diabet.2020.08.005_bib0185","article-title":"Prognostic value of Albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.diabet.2020.08.005_bib0190","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000503713","article-title":"Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial","volume":"50","author":"Bakris","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.diabet.2020.08.005_bib0195","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jacc.2011.04.049","article-title":"Eplerenone Survival Benefits in Heart Failure Patients Post-Myocardial Infarction Are Independent From its Diuretic and Potassium-Sparing Effects","volume":"58","author":"Rossignol","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2020.08.005_bib0200","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2020.08.005_bib0205","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1681\/ASN.2010030250","article-title":"Proteinuria in diabetes: Bystander or pathway to cardiorenal disease?","volume":"21","author":"Karalliedde","year":"2010","journal-title":"J Am Soc Nephrol"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363620301233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363620301233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:57:53Z","timestamp":1761130673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363620301233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1262363620301233"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2020.08.005","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2020.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101190"}}